New 2nd or 3rd Line Treatment for ALK+

A new 2nd or 3rd line treatment for patients with metastatic non-small cell lung cancer has been approved by the U.S. Food & Drug Administration! The medication, LORBRENA® (lorlatinib), is for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Thank you for your participation in the Bonnie J. Addario Lung Cancer Registry! This month we have exciting news to share with our ALK+ patients:

A new 2nd or 3rd line treatment for patients with metastatic non-small cell lung cancer has been approved by the U.S. Food & Drug Administration! The medication, LORBRENA® (lorlatinib), is for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

The approval of LORBRENA® is another advance in precision drug development and improving outcomes for patients with mutation-driven lung cancers. Click here to learn more information about this exciting new drug, and view the full prescribing information here.

Together we can make a difference as we continue the fight to end lung cancer.

Sandra Shaw
Director, Patient Registry
Bonnie J. Addario Lung Cancer Foundation
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lungcancerregistry.org